Investors have bet new drugs can topple Merck’s Keytruda, but the evidence so far points to something smaller.
Merck & Co., Inc. (NYSE:MRK) is one of the best cheap stocks to buy for beginners. Moderna, Inc. and Merck & Co., Inc.
Merck has rebounded 55% in the past year, driven by optimism around its post-Keytruda strategy despite the looming patent ...
Drugmakers including BioNTech, Merck & Co. and Pfizer are all testing their investigational PD-1/VEGF bispecifics against ...
Morning Overview on MSN
Intismeran autogene plus Keytruda dropped melanoma recurrence by close to 50% over five years in a Moderna-Merck-NYU trial unveiled at ASCO
Patients with high-risk melanoma who received a personalized mRNA cancer vaccine alongside Keytruda saw their risk of disease ...
After ICIJ’s The Cancer Calculus investigation exposed a market for falsified Keytruda, two sources confirmed Friday that ...
Morning Overview on MSN
An mRNA vaccine paired with Keytruda cut melanoma recurrence by nearly 50% over five years in a landmark NYU-led trial
Patients with high-risk melanoma who received a personalized mRNA cancer vaccine alongside pembrolizumab after surgery saw ...
Pfizer (NYSE:PFE) and Merck (NYSE:MRK) both just closed earnings chapters that frame the 2026 dividend debate clearly. Pfizer ...
A new mRNA melanoma vaccine from Merck and Moderna showed sustained benefits over five years, cutting the risk of cancer ...
Today we revisit the American Society of Clinical Oncology scientific meeting in Chicago, which concluded on Tuesday, to report on three more potentially practice-changing studies.
On May 12, 2026, the Patent Trial and Appeal Board (“PTAB”) issued a Final Written Decision (“FWD”) in PGR2025-00003 finding all challenged claims of Halozyme’s U.S. Patent No. 11,952,600 (“the ’600 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results